How Long Does Amphetamine Stay in Your System?

Amphetamine has an elimination half-life of roughly 6 to 12 hours, meaning it takes one to three days for most of the drug to leave your bloodstream after a single dose. But “your system” and “your blood” are not the same thing. A standard urine test can pick up amphetamine for up to five or even six days after use, an oral fluid swab for one to three days, and a hair test for months. The answer depends heavily on which test is being used, how much and how often you took the drug, and a handful of biological variables that shift the timeline in ways most people do not expect.

How Amphetamine Leaves the Body

Once swallowed, amphetamine is absorbed well and distributes widely, with a large volume of distribution (about 4 liters per kilogram of body weight) and low binding to blood proteins. Two exit routes handle most of the work: the liver metabolizes a portion of the drug, and the kidneys excrete the rest, some of it unchanged.¹ The balance between those two routes is what makes elimination times so variable from person to person.

On the liver side, the enzyme CYP2D6 plays a central role in breaking down amphetamine and related stimulants.² CYP2D6 is genetically variable: some people carry gene versions that make the enzyme work faster or slower than average. That variation is a significant source of the differences in how quickly two people clear the same dose of amphetamine.³ If you are a “poor metabolizer” of CYP2D6, the drug lingers longer; if you are an “ultrarapid metabolizer,” it clears faster.

On the kidney side, urine pH matters enormously. Amphetamine is a basic (alkaline) molecule. In acidic urine, it becomes ionized and cannot be reabsorbed back into the bloodstream through the kidney tubules, so more of it leaves in the urine. In alkaline urine, the reverse happens: the drug stays un-ionized, gets reabsorbed, and stays in circulation longer. A modeling study in the Journal of Pharmacology and Experimental Therapeutics showed that shifts in urine pH can dramatically change renal clearance and overall systemic exposure.⁴ Diet, hydration, certain medications, and even chronic conditions that alter acid-base balance can push urine pH in either direction, which is one reason two people who take the same dose can produce very different drug-test results days later.

Urine Testing

Urine is the most common matrix for drug screening, whether the context is workplace testing, probation, or clinical monitoring. At the standard immunoassay cutoff of 1,000 ng/mL, amphetamine can show up in urine for up to five days after a single dose. Drop the cutoff to 300 ng/mL and the detection window stretches roughly one day longer.⁵ For people who use amphetamine repeatedly or at high doses, the window can be even wider, because the drug accumulates in tissue before the kidneys can finish clearing it.

Workplace and federal testing programs in the United States typically use a two-step process. The initial immunoassay screen is fast and cheap but not perfectly specific. If it flags a sample, a confirmation test is run, usually with mass spectrometry, that identifies the exact drug and its concentration. The confirmation cutoffs for methamphetamine and amphetamine in federal workplace testing have historically been set at 500 and 200 ng/mL, respectively, though lower cutoffs have been proposed and studied.⁶ Lower cutoffs catch use farther out from the last dose, but they also raise the stakes for false positives, which is a topic worth its own discussion below.

Oral Fluid, Hair, and Sweat

Oral fluid (saliva) testing has gained ground in roadside and workplace settings because collection is harder to tamper with than urine. Amphetamine and methamphetamine concentrate in saliva at levels similar to or higher than those in plasma, which makes oral fluid a sensitive matrix for detecting recent use.⁷ After controlled oral dosing of lisdexamfetamine (a prodrug that the body converts to d-amphetamine), peak concentrations in oral fluid were almost six times higher than those in plasma, arriving about four hours after the dose.⁸ The practical detection window for a saliva test is generally one to three days, somewhat shorter than urine but useful for catching very recent use.

Hair testing operates on a completely different timescale. As hair grows, drugs circulating in the blood are incorporated into the hair shaft. A standard 1.5-inch hair sample represents roughly 90 days of growth. Segmental analysis, where the hair strand is cut into shorter pieces, can even estimate when during that window a drug was taken.⁹ The tradeoff is that hair cannot detect a dose taken within the past week or so, because it takes time for the drug to appear above the scalp line. Hair is better suited for establishing a pattern of use over months than for identifying what someone took yesterday.

Sweat patches are less common but show up in some criminal-justice monitoring programs. A patch worn on the skin collects drug excreted in perspiration over days or weeks. In a controlled study where participants received multiple 10-mg or 20-mg oral doses of methamphetamine, the drug was measurable in sweat within two hours of dosing. During the dosing week, the vast majority of weekly patches came back positive. Patches applied two weeks after the last low dose, however, were clean, and only a single patch was positive after the higher dose.¹⁰ Sweat patches effectively capture ongoing or recent use but do not have the long lookback window that hair provides.

Age, Kidney Health, and Other Physiological Variables

Children clear amphetamine faster than adults. In replicated pharmacokinetic studies, the average half-life in children was about 7 hours, compared with roughly 10 to 12 hours in adults.¹¹ This difference is one reason pediatric ADHD dosing schedules sometimes call for an afternoon booster: the drug may not last as long in a child’s body as it does in an adult’s.

Kidney function matters too. A study of lisdexamfetamine in people with varying degrees of renal impairment found that drug exposure (measured by the area under the concentration-time curve) rose as kidney function declined. In participants with end-stage renal disease, total body clearance of d-amphetamine was reduced by about half compared to those with healthy kidneys, and the drug’s half-life was substantially longer.¹² If you have chronic kidney disease, the drug stays in your system longer, and dosing adjustments are usually warranted.

Body composition, hydration status, and co-administered medications can also influence how long amphetamine lingers, though these effects are harder to quantify neatly. A larger volume of body water can dilute the drug, while certain medications that compete for the same liver enzymes can slow metabolism. The takeaway is that a single “detection window” number is always an average, and individual variation is the rule rather than the exception.

How the Formulation Changes the Timeline

Not all amphetamine products behave the same way in your body. Immediate-release tablets (like generic dextroamphetamine or mixed amphetamine salts) typically reach peak blood levels within two to three hours.¹¹ Taking an immediate-release dose twice a day results in afternoon blood concentrations roughly double those seen with a single morning dose of the same total amount, because the second peak rides on top of the tail from the first.¹³

Extended-release formulations like Adderall XR use bead technology to release part of the dose immediately and the rest hours later, mimicking twice-daily dosing in a single capsule.¹⁴ The peak may arrive a bit later and the overall plasma curve is stretched out, but the total amount of drug delivered is similar. Lisdexamfetamine (Vyvanse) takes yet another route: it is a prodrug that must be enzymatically split before active d-amphetamine is released. That rate-limited step pushes the time to peak concentration out to about 3 to 5 hours, and the resulting d-amphetamine half-life averages roughly 9 to 15 hours.¹⁵

From a drug-testing standpoint, what matters is that extended-release and prodrug formulations keep amphetamine in the bloodstream at measurable levels for a longer stretch after each dose. The total detection window in urine may not change radically for a single dose, since the body eventually clears the same molecule. But in people taking daily prescriptions, steady-state accumulation means the drug never fully clears between doses, and a urine test taken several days after the last dose could still come back positive.

False Positives and Why They Happen

The initial immunoassay screen used in most drug-testing programs works by recognizing the general shape of an amphetamine molecule, not by identifying the exact compound. That structural similarity is a feature for catching illicit drugs but a liability when other medications share a similar molecular backbone. A wide range of prescription and over-the-counter drugs have been documented to trigger false-positive amphetamine screens, including certain antidepressants (bupropion, trazodone, sertraline), antihistamines (brompheniramine, diphenhydramine), antipsychotics (chlorpromazine, promethazine, quetiapine), the stomach acid drug ranitidine, and nasal decongestants containing pseudoephedrine.¹⁶ A six-year review of false-positive amphetamine screens found that sildenafil (Viagra), bisoprolol, metoprolol, and tramadol also appeared among the culprits.¹⁷

One particularly well-studied scenario involves the Vicks VapoInhaler, an over-the-counter nasal decongestant that contains levomethamphetamine (l-methamphetamine). This is the “left-handed” mirror image of the illicit d-methamphetamine, and while it has decongestant properties, it has virtually no stimulant or abuse potential. Yet because the basic immunoassay cannot tell the two mirror forms apart, using a Vicks inhaler at recommended doses has been shown to produce false-positive results on at least one commonly used immunoassay platform.¹⁸ The same case report literature includes atomoxetine, a non-stimulant ADHD drug that structurally resembles amphetamine enough to trip certain screens.¹⁹

If you are taking any of these medications and face a drug screen, the single most important thing to know is that a positive immunoassay is not a final answer. You have the right to request confirmatory testing, and any reputable program should run one automatically before reporting a result to an employer or court.

Confirmatory Testing and Telling Left From Right

Confirmatory tests use mass spectrometry, which identifies molecules by their exact mass and fragmentation pattern rather than by broad structural similarity. This eliminates the vast majority of cross-reacting medications. But even mass spectrometry has a blind spot: it can tell you that methamphetamine or amphetamine is present, yet standard methods cannot distinguish the d-isomer (the one with stimulant effects, found in prescription medications and illicit drugs) from the l-isomer (found in the Vicks inhaler and as a metabolite of the prescription drug selegiline).

To solve that problem, laboratories use chiral separation, which adds a step to distinguish the two mirror-image forms. One established approach derivatizes the sample with a chiral reagent before running it through gas chromatography-mass spectrometry, converting the two isomers into compounds that separate on the column.²⁰ Newer liquid chromatography-mass spectrometry methods can accomplish the same thing in oral fluid samples, using a chiral column to separate the isomers directly.²¹ The result tells the lab (and the medical review officer) whether the methamphetamine in the sample is the d-form, which points to illicit use or a d-amphetamine prescription, or the l-form, which points to a Vicks inhaler or selegiline.

This distinction matters beyond the Vicks scenario. Prescription mixed amphetamine salts (Adderall, for instance) contain a 3:1 ratio of d-amphetamine to l-amphetamine. Someone taking that medication will have both isomers in their urine, in a predictable proportion. A chiral test that finds only the d-isomer, or a ratio inconsistent with mixed salts, can raise questions about whether the person is actually taking their prescription as directed or is obtaining amphetamine from another source. Chiral testing has therefore become an important tool not just for ruling out false positives but for monitoring medication adherence in pain and addiction clinics.

Methamphetamine and Its Relationship to Amphetamine on Tests

One point that confuses many people: methamphetamine is metabolized in the body partly into amphetamine. If someone uses methamphetamine, their urine will typically contain both methamphetamine and its metabolite amphetamine.²² Federal workplace testing rules handle this by requiring that amphetamine be present above a set threshold before a methamphetamine-positive result is reported, since the presence of amphetamine as a metabolite confirms that the methamphetamine was actually ingested rather than being a contaminant or analytical artifact.

The reverse, however, is not true: taking prescription amphetamine (dextroamphetamine, Adderall, Vyvanse) does not produce methamphetamine as a metabolite. So if a urine confirmation test shows amphetamine alone, there is no reason to suspect methamphetamine use. This one-way metabolic relationship is straightforward, but it trips people up when they read that “amphetamine showed up on my test” and worry it means something other than their prescription.

Prenatal and Neonatal Detection

Drug testing during pregnancy and at birth occupies a different niche. Meconium, the dark substance a newborn passes in the first few days, accumulates drugs the fetus was exposed to throughout the second and third trimesters. It has long been used as a specimen for detecting prenatal drug exposure.²³ However, a comparison study found that for amphetamines specifically, meconium was far less sensitive than maternal hair: all 18 amphetamine-positive cases identified by maternal hair testing came back negative in meconium, placenta, and umbilical cord samples. Meconium and other neonatal specimens tended to test positive only when hair analysis showed heavy and sustained use throughout pregnancy, especially in the third trimester.²⁴ For clinicians and parents navigating this situation, the practical implication is that a negative meconium result does not necessarily rule out all amphetamine exposure during pregnancy; it may simply mean exposure was intermittent or occurred earlier in gestation.